HealthTab Signs Agreement for More Rexall Pharmacy Locations
HealthTab Signs Agreement for More Rexall Pharmacy Locations
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce further expansion of HealthTab with Rexall Pharmacy Group ULC ("Rexall"). The Companies have been working closely to develop the best patient approaches and internal workflows to ensure the most successful deployment of this powerful point-of-care testing platform.
不列颠哥伦比亚省温哥华,2024 年 4 月 4 日(GLOBE NEWSWIRE)— Avricore Health Inc (多伦多证券交易所股票代码:AVCR,场外交易代码:AVCRF)(“Avricore Health” 或 “公司”)欣然宣布与Rexall Pharmacy Group ULC(“Rexall”)进一步扩展HealthTab。两家公司一直在密切合作,开发最佳的患者方法和内部工作流程,以确保最成功地部署这个强大的即时护理测试平台。
"To successfully screen and manage chronic and infectious disease, healthcare systems need pharmacists to play an active role," said Hector Bremner, CEO of Avricore Health. "To do this well pharmacists need the best tools to have confidence in their results and the data to drive deeper insights."
Avricore Health首席执行官赫克托·布雷姆纳说:“为了成功筛查和管理慢性病和传染病,医疗保健系统需要药剂师发挥积极作用。”“要做到这一点,药剂师需要最好的工具来对自己的结果充满信心,也需要数据来获得更深入的见解。”
Last September, the Company announced its first testing location within Rexall's Pharmacy Walk-In Clinic in Sherwood Park, Alberta. That location, a first for Rexall as well, offers both the Afinion 2 blood-chemistry analyzer as well as the ID Now molecular platform by Abbott Rapid Diagnostics, giving patients quick access to their test results, and allowing for immediate consultation with their pharmacist.
去年9月,该公司宣布在艾伯塔省舍伍德公园的Rexall药房步入式诊所内设立首个测试地点。该地点也是Rexall的首个地点,它既提供Afinion 2血液化学分析仪,也提供雅培快速诊断的ID Now分子平台,使患者可以快速获得测试结果,并可以立即咨询药剂师。
The next steps will be to deploy a minimum of another 20 locations spread out between stores in Alberta and Ontario. After each deployment, the teams will collaborate to assess deployment workflow, refine processes and identify further deployment opportunities based on patient and pharmacist feedback.
下一步将是至少再部署20个地点,分布在艾伯塔省和安大略省的门店之间。每次部署后,各团队将合作评估部署工作流程,完善流程,并根据患者和药剂师的反馈确定进一步的部署机会。
With approximately 800 locations across Canada, HealthTab is expected to deepen its reach and empower more patients, and pharmacists, with health data insights that will drive better treatment plans, therapy adherence and patient outcomes.
HealthTab在加拿大拥有约800个分支机构,预计将扩大其覆盖范围,为更多的患者和药剂师提供健康数据见解,这将推动更好的治疗计划、治疗依从性和患者疗效。
About Rexall
关于 Rexall
With a dynamic history of innovation and growth dating back over a century, Rexall is a leading pharmacy retailer in Canada, dedicated to caring for Canadians' health, one person at a time. Operating approximately 400 pharmacies across Canada, Rexall's 8,000 employees provide compassionate care to patients, becoming their trusted health partners along their wellness journey.
Rexall是一家加拿大领先的药房零售商,其充满活力的创新和增长历史可以追溯到一个多世纪以前,致力于为加拿大人提供一个人的健康。Rexall在加拿大经营约400家药店,8,000名员工为患者提供富有同情心的护理,成为他们健康之旅中值得信赖的健康合作伙伴。
Rexall is part of the Rexall Pharmacy Group ULC and a proud member of the global McKesson Canada Corporation family, a diversified healthcare company with deep roots in supporting patients across Canada.
Rexall是Rexall Pharmacy Group ULC的一部分,也是加拿大麦克森公司全球大家庭的骄傲成员。麦克森是一家多元化的医疗保健公司,在为加拿大各地的患者提供支持方面有着深厚的基础。
For more information, visit rexall.ca. Follow us on Twitter: @RexallDrugStore, on Instagram at @RexallDrugStoreOfficial, and @RexallCareNetwork and on Facebook at @RexallDrugStore
欲了解更多信息,请访问 rexall.ca。请在推特上关注我们:@RexallDrugStore、Instagram 上的 @RexallDrugStoreOfficial、@RexallCareNetwork 和脸书上的 @RexallDrugStore
HealthTab Market Fast Facts
HealthTab 市场速览
- Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source)
- Nearly 13.6 Million Canadians are expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source)
- Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
- Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source)
- There are more than 10,000 pharmacies in Canada, 88,000 pharmacies in the US, and nearly 12,000 in the UK.
- 即时护理测试市场将在2030年达到932.1亿美元(来源)
- 到2030年,预计将有近1360万加拿大人患有糖尿病或糖尿病前期,其中许多人未被诊断(来源)
- 超过三分之一的美国人(约8,800万人)患有糖尿病前期(来源)
- 每年有将近16万名20岁及以上的加拿大人被诊断出患有心脏病,通常是在心脏病发作后才被诊断出患有心脏病。(来源)
- 加拿大有超过10,000家药房,美国有88,000家药房,英国有近12,000家药房。
About HealthTab
关于健康选项卡
HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real-time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
HealthTab 是一站式即时医疗测试解决方案,它将一流的即时医疗技术与安全的基于云的平台相结合,用于解决紧迫的全球健康问题。只需从手指刺中滴下几滴血,该系统即可当场生成实验室准确的结果,并实时报告数据。测试菜单包括多达23种关键生物标志物,用于筛查和管理慢性病,例如糖尿病和心脏病(例如HbA1c、脂质谱、eGFR)。HealthTab 最近还增加了细菌和病毒检测功能,例如链球菌和 COVID-19。
The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real-world data (RWD) sets, and third-party app integration through API.
HealthTab网络模型与当今药房中的任何模型都不一样。它使知识渊博且值得信赖的药剂师在初级保健提供中发挥更大的作用,同时使患者能够更好地控制自己的健康。它还降低了成本和等待时间,并提供了许多潜在的收入来源,包括设备租赁和消耗品、直接访问测试、疾病预防和管理计划、赞助的健康计划、分散的临床试验、真实世界数据 (RWD) 集以及通过API进行第三方应用程序集成。
About Avricore Health Inc.
关于 Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.
Avricore Health Inc.(多伦多证券交易所股票代码:AVCR)是一家药房服务创新者,专注于收购和开发旨在推动药房向前发展的早期技术。通过其旗舰产品HealthTab(一家全资子公司),该公司的使命是通过在社区药房创建世界上最大的快速检测设备网络,让所有人更容易获得可操作的健康信息。
Contact:
联系人:
Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
Avricore Health Inc
赫克托·布雷姆纳,首席执行官 604-773-8943
info@avricorehealth.com
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
关于前瞻性陈述的警示说明
本新闻稿中涉及Avricore Health对未来的预期、计划、意图或战略的信息均为前瞻性陈述,不是事实,涉及许多风险和不确定性。Avricore Health 通常使用诸如 “展望”、“将”、“可能”、“可能”、“保留”、“未来”、“计划”、“相信”、“可能”、“期望”、“打算”、“预期”、“估计”、“未来”、“定位”、“潜在”、“项目”、“保留”、“计划”、“计划”、“计划”、“计划”、“计划”、“计划”、“设定”、“设定”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“计划”、“计划”” “受制于”、“即将到来” 和类似的表述,以帮助识别前瞻性陈述。在本新闻稿中,前瞻性陈述包括有关配售完成及其预期时间以及公司对配售收益的预期用途的陈述;HealthTab平台为药剂师和患者提供的独特功能。前瞻性陈述反映了Avricore Health管理层当时的预期、信念、假设、估计和预测。本新闻稿中的前瞻性陈述基于Avricore Health截至本新闻稿发布之日获得的信息。前瞻性陈述被认为是真实的,最终可能会被证明是不正确的。这些声明不能保证Avricore Health的未来表现,并且受一些风险、不确定性和其他因素的影响,其中一些因素是其无法控制的,可能导致实际业绩与当前的预期存在重大差异,包括但不限于:未能满足监管要求;市场变化;经济状况的潜在衰退;以及Avricore公开文件中描述的其他风险因素。这些前瞻性陈述仅代表其发表之日,除非法律另有要求,否则公司没有义务公开更新这些陈述以反映新信息或未来事件或情况的发生。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
多伦多证券交易所风险交易所及其监管服务提供商(该术语在多伦多证券交易所风险交易所的政策中定义)均不对充分性或准确性承担责任 发布的内容。